[HTML][HTML] Quantifying renal allograft loss following early antibody-mediated rejection
Unlike antibody-mediated rejection (AMR) with clinical features, it remains unclear whether
subclinical AMR should be treated, as its effect on allograft loss is unknown. It is also
uncertain if AMR's effect is homogeneous across donor (deceased/live) and (HLA/ABO)
antibody types. We compared 219 patients with AMR (77 subclinical, 142 clinical) to controls
matched on HLA/ABO-compatibility, donor type, prior transplant, panel reactive antibody
(PRA), age and year. One and 5-year graft survival in subclinical AMR was 95.9% and …
subclinical AMR should be treated, as its effect on allograft loss is unknown. It is also
uncertain if AMR's effect is homogeneous across donor (deceased/live) and (HLA/ABO)
antibody types. We compared 219 patients with AMR (77 subclinical, 142 clinical) to controls
matched on HLA/ABO-compatibility, donor type, prior transplant, panel reactive antibody
(PRA), age and year. One and 5-year graft survival in subclinical AMR was 95.9% and …